Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VNDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares.
View VNDA analyst ratings or view top-rated stocks.

1 brokerages have issued 12-month price targets for Vanda Pharmaceuticals' shares. Their VNDA share price forecasts range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 21.5% from the stock's current price.
View analysts price targets for VNDA or view top-rated stocks among Wall Street analysts.

Vanda Pharmaceuticals' stock was trading at $15.69 at the start of the year. Since then, VNDA shares have decreased by 37.0% and is now trading at $9.88.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our VNDA earnings forecast.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a net margin of 4.18% and a trailing twelve-month return on equity of 2.19%. During the same period last year, the company posted $0.11 EPS.

Vanda Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240.00 million-$280.00 million, compared to the consensus revenue estimate of $265.10 million.

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VNDA stock can currently be purchased for approximately $9.88.

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $558.81 million and generates $268.68 million in revenue each year. The biopharmaceutical company earns $33.15 million in net income (profit) each year or $0.20 on an earnings per share basis.

The company employs 278 workers across the globe.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.